recent post

Biju Nair joins Care Hospitals as zonal COO in Hyderabad

November 4, 2024
recent post

Ramaiah Memorial Hospital launches Ramaiah Stroke Center

recent post

Herbalife India, IIT Madras launch 1,000 data science scholarships

recent post

KIMSHEALTH Nagercoil launches modular OT complex

recent post

Bayer introduces Bepanthen in India to tackle dry skin

Wanbury’s Patalganga manufacturing facility clear US FDA inspection with zero observations

Wanbury's Patalganga manufacturing facility clear US FDA inspection with zero observations

Wanbury exports APIs to more than 70 countries including the US, Europe and Latin America Pharma company Wanbury, having a presence in the API global market and domestic branded formulation announced the successful completion of the United States Food & Drug Administration (US FDA) inspection at the Patalganga site, Maharashtra. The inspection was concluded with zero-483 observations. Mohan Rayana, Director, Wanbury said, “We are pleased to announce the successful completion of the US FDA inspection at our Patalganga site, resulting in zero Form 483 observations. This achievement underscores our commitment to the highest quality and compliance standards at both our API manufacturing sites in Patalganga, Maharashtra, and Tanuku, Andhra Pradesh, both of which are US FDA approved.”  Wanbury exports APIs to more than 70 countries including the US, Europe and Latin America.